Report: Best Practices for Patient Digital Engagement in EU5

September 28, 2017

Digital competitive landscape review of pharma's leading innovators and best practices

In-depth review of pharma’s patient digital initiatives, leading innovators, how patients are engaging with them, and best practices.

Based on analysis of 132 digital assets and Manhattan Research study findings of 3,047 EU5 consumers’ pharma engagement preferences. 

 

This report helps marketers, multichannel teams and commercial leaders:

  • Understand the extent of your competitors’ digital outreach, including disease awareness, patient education and support and more
  • Benchmark digital patient models and strategies against competitors
  • Learn which innovators are winning and why
  • Implement best practices and prioritize the right content and support
  • Validate your plans and justify investment in digital

 

Report fast facts:

  • Easy-to-digest visuals of patient digital models and best-in-class examples
  • Digital assets reviewed: Branded and unbranded websites, apps, patient support portals, social networks and more in France, Germany, Italy, Spain and the UK
  • Companies reviewed include Sanofi, GSK, Novartis, Pfizer, Merck, and BMS
  • Therapy areas reviewed: Diabetes, rheumatoid arthritis, oncology, multiple sclerosis, psoriasis, endocrinology, respiratory

 

Topics covered include:

  • Visual summary of key takeaways and recommendations

 

Patient digital engagement models

  • Website and digital asset strategies adopted by competitors
  • Strengths and weaknesses of each model
  • Comparison of engagement models by country and company

 

Digital strategy and tactics

5 key characteristics of patient digital innovation
 
Best practices and best-in-class examples:
  • Patient education and content
  • Patient support resources
  • User experience and navigation
  • Digital channel integration and distribution tactics
 
Pharma’s patient innovation leaders

 

Contact us for sample report insights or to talk to an analyst:

Previous Article
Checking in on telemedicine adoption
Checking in on telemedicine adoption

Telemedicine was supposed to change the practice of medicine in the U.S. How’s it coming? Slowly, as state-...

Next Article
Pharma brands: to drive patient behavior, get to know the “why” behind it….
Pharma brands: to drive patient behavior, get to know the “why” behind it….

How pharma brands can leverage social intelligence and emotional analysis to better understand patient beha...